India: Publici Juris – In Pharma Products

Last Updated: 18 December 2006
Article by Manisha Singh Nair

"Publici juris" is a Latin word, and in the legal parlance, means, "of public right." The term signifies a thing or a right that is open and exercisable by all persons. It designates things that belong to the entire community, and not to any private party.

Usually, common suffixes or prefixes do not come in the way of distinctiveness. The nature of certain trades may require common suffix/ prefix for the purpose of familiarity. The distinctive nature of the word would then depend on the remaining part of the word attached to these common suffixes and prefixes. A term would be considered as a prefix or suffix only if they are derived from common or generic words. It is in this scenario the case under comment comes into limelight. The Madras High Court in Apex Laborataries Ltd v. Zuventus Health Care Ltd, 2006 (33) PTC 492 (Mad.)(DB) ruled that "Zincovit" and "Zinconia" are two words phonetically dissimilar and the visual impressions are also different and hence, it is hardly likely to cause confusion.


Apex laboratories Limited (Appellants), the manufacturers of the Pharmaceutical products adopted trademark "Zincovit in 1988. It is their claim that they have at times filed case against infringement of their said mark and secured injunctions. In early 2006, they came to know that the respondents were carrying on trade under the trademark "Zinconioa." It is alleged that the respondents are guilty of infringement and passing off and hence have filed the civil suit and injunction.

The respondents on the other hand resisted the application raising the contention that there are several registered trademark owners registered with the word ‘Zinco." Further, there is no likelihood of confusion as there is no phonetic, visual or conceptual similarity is attached to the said marks. The exparte injunction already granted was vacated on the ground that there is no likelihood of confusion in the minds of the purchaser.

The appeal preferred by the Apex Laboratories is against the vacation of expatre injunction.


A catena of cases was cited for substantiating the contentions. The court referred to Ciba Geigy Limited & Hindustan Ciba-Geigy Ltd. v. Croslands Research Laboratories Ltd., 1995 IPLR 375; where the division bench granting the injunction held that EUGEL was strikingly similar to EMULGEL.


On the question of similarity, which being the moot issue in this case, the Court relied on Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd., 2001 PTC 300(SC), where the apex court held that the drug even if sold under the prescription or only to the physicians cannot itself be considered as a sufficient ground against confusion. The factors to be adequately considered for deciding the question of similarity are

  1. The nature of marks i.e. where it is a word mark or label mark or composite mark;
  2. The degree of resemblances;
  3. The nature of goods;
  4. The similarity in nature, character, performance of rival traders;
  5. The class of purchasers;
  6. The mode of purchasing the goods;
  7. The other surrounding circumstances;

The court for buttressing the conclusion relied on Corn Products Refining Co. v. Shangria Food Products Ltd, AIR 1960 SC 142; where it was held that the question whether the two marks are likely to give rise to confusion or not is a question of first impression.

On the question of generic term and publici juris, the court buttressed the argument by relying on SBL LTD. v. Himalaya Drug Co, 1997 (17) PTC (DB) and Roche & Co. v. G. Manner & Co, AIR 1970 SC 2062; where it was categorically held that no one can claim an exclusive right to a generic term and the customer will not consider the common feature and would pay more attention to the descriptive features. It is common in the pharmaceutical trade that abbreviations for vitamins and chemical names are extensively used. The court observes that if the term is both descriptive and common to the trade, more attention is to be paid to the uncommon element in the two words, and then there would not be any confusion.

The present Court engineered with the above precedents held that as both the medical preparations contains ‘Zinc’ and that the word is common to the trade and hence it is definitely publici juris. The Apex Laboratories have no right to claim ownership over the above word and as both the trade names contain the word ‘Zinc, it would be dangerous to split the word into two and grant injunction. Cardboard cartons were produced before the court to substantiate the claim that there were broad dissimilarities and the court was convinced to the same. The court ruled that ‘Zincovit’ and ‘Zinconia’ are phonetically dissimilar and the visual impressions are also different and hence there is least chance for causing confusion and there by the appeal is dismissed.


The rules regarding deceptive similarity take a special connotation with regard to pharmaceutical trade names. As the drugs are prescribed by registered medical practitioners and dispensed by qualified pharmacists, the chances of confusion arising out of two products being deceptively similar are considerably reduced. To this extent, some similarity is allowed. Further many names are common to the trade and hence fall under publici juris, but it is always a matter of concern for the judiciary, where to draw the line, as whose impression is to be weighed, literates’ or illiterate’s, in deciding trademarks cases. It is clear from the precedents that the matter is not yet crystallized, and judicial mind is required to be exercised in each case according to the facts and circumstances.

© Lex Orbis 2006

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.